Rights and permissions
About this article
Cite this article
Fiscal impact of antiparkinsonian drugs in Germany. Pharmacoecon. Outcomes News 158, 8–9 (1998). https://doi.org/10.1007/BF03277545
Published:
Issue Date:
DOI: https://doi.org/10.1007/BF03277545